Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASIL: Refametinib plus Sorafenib in First-Line HCC
NCT01204177Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2010
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of refametinib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started Dec 2010; status: completed.
02
Drugs
refametinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01204177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204177.